Seizert Capital Partners LLC Has $4.13 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Seizert Capital Partners LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 49,264 shares of the biopharmaceutical company’s stock after acquiring an additional 119 shares during the quarter. Seizert Capital Partners LLC’s holdings in Gilead Sciences were worth $4,130,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. TFB Advisors LLC lifted its holdings in shares of Gilead Sciences by 1.2% in the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after purchasing an additional 116 shares in the last quarter. Sumitomo Life Insurance Co. raised its position in Gilead Sciences by 0.7% during the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after buying an additional 117 shares during the period. FDx Advisors Inc. lifted its stake in Gilead Sciences by 2.2% in the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 117 shares in the last quarter. Sivia Capital Partners LLC boosted its position in Gilead Sciences by 3.9% during the 3rd quarter. Sivia Capital Partners LLC now owns 3,249 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 123 shares during the period. Finally, Roberts Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 1.9% in the third quarter. Roberts Wealth Advisors LLC now owns 7,035 shares of the biopharmaceutical company’s stock worth $599,000 after purchasing an additional 130 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $88.40 on Friday. The firm has a 50 day moving average of $86.68 and a 200-day moving average of $76.04. The company has a current ratio of 1.26, a quick ratio of 0.82 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The stock has a market capitalization of $110.17 billion, a P/E ratio of 982.22, a price-to-earnings-growth ratio of 2.72 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the company posted $2.29 earnings per share. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.38 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.48%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Barclays increased their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $75.00 to $81.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Finally, Citigroup started coverage on shares of Gilead Sciences in a report on Thursday. They issued a “buy” rating and a $125.00 price objective for the company. Eleven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $93.86.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This represents a 27.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,947 shares of company stock worth $4,968,674. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.